| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Medical Sciences, University of Birmingham, Institute of Biomedical Research (J.E.C., J.M.H., H.F., J.C.-S., J.A.F., S.C.L.G.), Birmingham B15 2TT, United Kingdom; Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge (J.M.M.H.), Cambridge CB2 2XY, United Kingdom; and Division of Medical Sciences, University of Birmingham, Heartlands Hospital (S.C.L.G.), Birmingham B9 5SS, United Kingdom
Address all correspondence and requests for reprints to: Dr. S. C. L. Gough, Department of Medicine, University of Birmingham, Heartlands Hospital, Bordesley Green East, Birmingham, United Kingdom B9 5SS. E-mail: s.c.gough{at}bham.ac.uk.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Here, we have resequenced the exons of Tg, confirming the presence of the novel SNPs of the U.S. study and have performed a case-control association study of AITD patients and control subjects to elucidate whether these SNPs are also associated with the development of AITD in a United Kingdom (UK) Caucasian population.
| Subjects and Methods |
|---|
|
|
|---|
One thousand two hundred and fourteen Caucasian patients of UK origin with AITD (960 with GD and 254 with AH) were recruited from the thyroid clinics, as described previously (12, 13). Briefly, patients with GD were defined by the presence of biochemical hyperthyroidism together with two of the following criteria: diffuse goiter; significant titer of thyroid peroxidase, Tg, or TSH-R autoantibodies; or the presence of thyroid eye disease. Thyroid eye disease was classified using the NOSPECS classification, with disease being defined as positive features in any of classes 26 (14). AH was defined by the presence of positive thyroid autoantibodies (thyroid peroxidase and/or Tg) and biochemical evidence of hypothyroidism. Thyroid peroxidase and Tg antibodies were measured by gelatin particle agglutination (SERODIA-ATG, Fujirebio, Inc., Tokyo, Japan), and a titer of 1:100 was considered significant for both assays. TSH-R antibody status was determined by a radioinhibition method (RSR Ltd., Cardiff, UK), and a value of 10 U/liter or more was deemed significant after comparison with 50 control subjects obtained from the local blood transfusion service. Four hundred and eighty control subjects with no history of autoimmune disease had blood drawn at various sites, including the Blood Transfusion Service, Birmingham Heartlands Hospital, and the Queen Elizabeth Hospital, Birmingham. Control subjects were matched with patients for age, gender, and ethnicity, and all patients and control subjects had white Caucasian grandparents of UK origin. The study was approved by the local research ethics committees, and all subjects gave informed, written consent.
DNA was extracted from the whole blood of subjects using the Nucleon Bacc II kit from Tepnel Life Sciences PLC (Manchester, UK).
Sequencing of the human Tg gene exons
Exonic sequences (accession nos. X06068, AH008122, and AF169662) were obtained from GenBank (accessed through www.ncbi.nlm.nih.gov/) and aligned to genomic clones of human Tg [accession nos. AF230667 (exons 10 and 12) and AF305872 (exon 33)] using a basic local alignment search tool (BLAST) (www.ncbi.nlm.nih.gov/BLAST/) to enable primers to be designed approximately 100 bp upstream of the 5' intron-exon junction and approximately 100 bp downstream of the 3' intron-exon junction. Primers were designed using DNASTAR (DNASTAR Inc., Madison, WI; primer sequences shown in Table 1
). Genomic DNA from 32 control subjects (16 males and 16 females) was amplified by PCR using these primers (Sigma-Genosys, Haverhill, UK; PCR product sizes shown in Table 1
), and products were sequenced using an ABI 377 DNA sequencer (PE Applied Biosystems, Warrington, UK). The four SNPs in exons 10, 12, and 33, respectively (E10SNP24, E10SNP158, E12SNP, and E33SNP), were confirmed manually by comparison with Tg clone sequences (accession nos. AF230667 and AF305872).
|
Genomic DNA from 960 GD patients (254 AH patients and 480 control subjects) was amplified using PCR (primer sequences in Table 1
) for the SNPs E10SNP24, E10SNP158, E12SNP, and E33SNP. Annealing temperatures were 53 C (E10SNP24 and E10SNP158), 56 C, and 54 C, respectively. SNP genotyping was performed using restriction fragment length polymorphism (RFLP), where PCR products were digested using restriction enzymes (New England Biolabs, Hitchin, UK; Table 1
) according to the manufacturers guidelines. RFLP fragment sizes are given in Table 1
, and all products were visualized on 3% agarose gels stained with ethidium bromide.
Statistical analyses
Analysis of the data were performed using the
2 test (MINITAB version 10.2), where P < 0.05 was considered significant.
Linkage disequilibrium (LD) was calculated among the four SNPs and between each of the SNP control subjects. LD was calculated using the COCAPHASE program (15, 16) to give D' values between 0 and 1. A D' value of 0 indicates no LD between markers, and a D' value of 1 indicates complete LD given the allele frequencies at each of the loci.
Multiple logistic regression was performed on case-control data using STATA (www.stata.com) with software written by David Clayton for use within that package (www.gene.cimr.cam.ac.uk/clayton/software/stata) to model genotype effects of the four Tg SNPs with respect to HLA-DR3 genotypes. This was to establish whether Tg and HLA-DR3 were interacting to increase disease risk.
| Results |
|---|
|
|
|---|
Allele frequencies and genotype distributions for the four Tg SNPs were similar in the AITD cases and control subjects (summarized in Table 2
). There was no evidence for an independent association with either GD or AH (summarized in Table 3
). All genotypes were in Hardy-Weinberg equilibrium. Power calculations showed that we had greater than 94% power to detect an effect if present, with an odds ratio of 1.5 and P = 0.001.
|
|
LD was calculated among the four SNPs (Table 4
). Strong LD was only detected between the two exon 10 SNPs, E10SNP24 and E10SNP158 (D' = 0.96).
|
Multiple logistic regression (using both multiple degrees of freedom and 1 degree of freedom) showed no evidence for an interaction of any of the four Tg SNPs with HLA-DR3 to either increase or decrease disease risk (Table 5
).
|
| Discussion |
|---|
|
|
|---|
Recent studies have investigated the role of Tg in AITD (8, 9, 10, 11) and have led to the publication of independent reports of linkage and association of the Tg region with both GD and AH. Tomer et al. (9) initially found association of a microsatellite marker in the Tg region with AITD in a case-control dataset, although association in the family dataset was with different alleles. We subsequently reported weak association of a rare intron 27 Tg microsatellite allele with AITD (2.2% of AITD cases and 0.25% of control subjects;
2 = 24.97; P < 0.001) in the same dataset as that used in the present study, although we explained that the finding could be the result of a random chance event (10). The latest study by Ban et al. (11), involving a comprehensive screening of all Tg exons and genotyping in 435 subjects, showed association of four novel Tg SNPs with AITD. In the present study examining the same SNPs as those studied by Ban et al. (11), we found no evidence of allelic association despite our study having greater than 94% power to detect an effect using conservative odds ratios smaller than those reported.
In our current study of 1214 AITD patients, we have not routinely measured Tg autoantibodies. However, of 380 subjects tested for Tg autoantibodies, 148 (38.9%) were found to have positive titers. The allele frequencies of the four candidate SNPs in this subgroup of patients with positive Tg autoantibody titers were not significantly different from those in subjects with negative Tg autoantibody titers. It is, therefore, unlikely that the Tg polymorphism is involved in the induction of Tg autoantibodies, although data from subgroup analysis with reduced numbers should be interpreted with caution. Furthermore, separate subgroup analysis of the four Tg SNPs in patients with GD and AH revealed no differences in allele frequencies compared with control subjects. Similarly, no significant differences in allele frequencies of the four Tg SNPs were observed between males and females when comparing AITD patients and control subjects (data not shown).
The most important factors underlying the inability to replicate reports of allelic association are publication bias (20), failure to attribute results to chance (20), and inadequate sample sizes (21). Adequately sized datasets are important to prevent the generation of false positive (type I errors) and false negative (type II errors) results (21). A meta-analysis by Lohmueller et al. (22) showed that only about one quarter of positive association studies actually represent real associations, which emphasizes the need for highly powered datasets. This combined with a number of studies that have failed to replicate associations with initial significances below the accepted threshold of P < 0.05 have led to the suggestion that the threshold should be lowered to 105 even with regions containing good candidate loci (23). The best evidence for association between Tg and AITD is seen in the study by Ban et al. (24), although with a P < 10-3 this could still be a false positive result due to sample size (42% power, with an OR of 1.56 and P = 0.001). It is, of course, possible that Tg contributes to AITD susceptibility in the U.S. and not the UK, and this remains an important alternative explanation, as exemplified by studies showing racial differences in susceptibility to AITD (24).
Evidence was also provided in the study by Ban et al. (11) to support a strong interaction between the exon 33 SNP and HLA DR3. Such an effect would be attractive, because a cysteine-rich domain of invariant chain, a protein that facilitates folding of the major histocompatibility complex class II molecules, has remarkably high homology to the cysteine-rich repetitive elements in Tg (25). Koch et al. (25) suggested that these homologous domains may play a role in hormone formation or intracellular molecule transport. A subsequent study (26) showed that mutations in the antigen-binding pockets of HLA-DR3 hinder the release of class II-associated invariant chain peptides from DR3 molecules, which must take place before antigenic peptides can be bound. This together with the reports by Ban et al. (11) of interaction between Tg and HLA-DR3 to increase AITD susceptibility led us to investigate interaction of the four Tg SNPs with HLA-DR3. We found no evidence of statistical interaction between any of the Tg SNPs with HLA-DR3 when using multiple logistic regression with multiple or single degrees of freedom. Hence, the most consistently associated allele of the HLA region does not appear to interact in any way with the four Tg SNPs to increase susceptibility to disease over and above that already seen with HLA-DR3 in the UK.
Although this is the largest dataset to study the Tg in AITD, we still cannot exclude this gene region as harboring a causal variant for AITD in the UK. A more comprehensive analysis of chromosome 8q24, including a wider range of SNPs in Tg and neighboring genes in a large, well matched dataset, is required to determine whether a causal variant within any one of a number of candidates in this linked region is conferring susceptibility to AITD.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: AH, Autoimmune hypothyroidism; AITD, autoimmune thyroid disease; GD, Graves disease; HLA, human leukocyte antigen; LD, linkage disequilibrium; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism; Tg, thyroglobulin; TSH-R, TSH receptor.
Received July 9, 2004.
Accepted September 7, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Huber, F. Menconi, S. Corathers, E. M. Jacobson, and Y. Tomer Joint Genetic Susceptibility to Type 1 Diabetes and Autoimmune Thyroiditis: from Epidemiology to Mechanisms Endocr. Rev., October 1, 2008; 29(6): 697 - 725. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |